Abstract
These recommendations update information on the vaccine and antiviral agents available for controlling influenza during the 1996-97 influenza season (superseding MMWR 1995;44(No. RR-3):1-22). The principal changes include information about a) the influenza virus strains included in the trivalent vaccine for 1996-97 and b) extension of the optimal time for influenza vaccination campaigns for persons in high-risk groups.
Publication types
-
Guideline
-
Practice Guideline
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Amantadine / adverse effects
-
Amantadine / therapeutic use
-
Antiviral Agents / adverse effects
-
Antiviral Agents / therapeutic use*
-
Child
-
Child, Preschool
-
Contraindications
-
Drug Interactions
-
Female
-
Humans
-
Immunization Programs
-
Immunization Schedule
-
Infant
-
Infection Control / standards
-
Influenza A virus / immunology*
-
Influenza B virus / immunology*
-
Influenza Vaccines / administration & dosage*
-
Influenza Vaccines / adverse effects
-
Influenza, Human / drug therapy
-
Influenza, Human / epidemiology
-
Influenza, Human / prevention & control*
-
Middle Aged
-
Pregnancy
-
Rimantadine / adverse effects
-
Rimantadine / therapeutic use
-
Risk Factors
-
United States
-
Vaccination / adverse effects
-
Vaccination / standards*
-
Vaccines, Inactivated / administration & dosage*
-
Vaccines, Inactivated / adverse effects
Substances
-
Antiviral Agents
-
Influenza Vaccines
-
Vaccines, Inactivated
-
Rimantadine
-
Amantadine